Sparrow Therapeutics Exit Strategy

Dzidziso Samuel Kamuriwo and Charles Baden–Fuller

Entrepreneurship Theory and Practice, 2014, vol. 38, issue 3, 691-708

Abstract: The case focuses on Ken Powers, cofounder and chief executive officer of Sparrow Therapeutics, whose young biotechnology company has reached a critical stage where he has to decide whether or not to sell. The company's three main sets of investors have different priorities: (1) a quick cash sale now, (2) delay sale for about a year if returns are greater, and (3) delay sale for 2 years, build company value, and retain autonomy. What choice would be best for the company, for its investors—and for Ken himself? And when would be the best time to implement the exit strategy?

Date: 2014
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1111/etap.12003 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:entthe:v:38:y:2014:i:3:p:691-708

DOI: 10.1111/etap.12003

Access Statistics for this article

More articles in Entrepreneurship Theory and Practice
Bibliographic data for series maintained by SAGE Publications ().